Related Experiment Videos

Galantamine in the treatment of vascular dementia

H Robert Brashear1

  • 1Department of Neurology, University of Virginia Health Services, Charlotte, Virginia, USA. RBrashea@prdus.jnj.com

International Psychogeriatrics
|September 30, 2005
PubMed

Insights

Vascular dementia (VaD) and Alzheimer's disease (AD) share cognitive decline. A trial showed galantamine offers clinically relevant benefits for patients with VaD or AD with cerebrovascular disease.

Area of Science:

  • Neurology
  • Neuroscience
  • Pharmacology

Background:

  • Vascular dementia (VaD) and Alzheimer's disease (AD) present similar progressive declines in cognition, function, and behavior.
  • Reduced cholinergic neurotransmission is implicated in both VaD and AD.
  • Current VaD treatments primarily focus on prevention, with limited evidence of cognitive benefits.

Purpose of the Study:

  • To evaluate the efficacy of acetylcholinesterase inhibitors as a symptomatic therapy for VaD.
  • To assess the clinical benefits of galantamine in patients with VaD or AD with cerebrovascular disease (AD + CVD).

Main Methods:

  • A large-scale, placebo-controlled trial was conducted.
  • Participants included patients diagnosed with VaD or AD + CVD.

Main Results:

  • The trial demonstrated clinically relevant benefits of galantamine in the studied patient populations.
  • This represents the first placebo-controlled trial to show such benefits in VaD or AD + CVD.

Conclusions:

  • Acetylcholinesterase inhibitors, specifically galantamine, show promise for symptomatic treatment of VaD.
  • Galantamine offers a potential therapeutic option for patients experiencing cognitive decline due to vascular factors or co-existing AD and cerebrovascular disease.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...